ID   TOP2B_HUMAN             Reviewed;        1626 AA.
AC   Q02880; Q13600; Q9UMG8; Q9UQP8;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   31-JAN-2002, sequence version 3.
DT   18-JUN-2025, entry version 246.
DE   RecName: Full=DNA topoisomerase 2-beta;
DE            EC=5.6.2.2 {ECO:0000255|PROSITE-ProRule:PRU00995, ECO:0000269|PubMed:10684600};
DE   AltName: Full=DNA topoisomerase II, beta isozyme;
GN   Name=TOP2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1333583; DOI=10.1093/nar/20.21.5587;
RA   Jenkins J.R., Ayton P., Jones T., Davies S.L., Simmons D.L., Harris A.L.,
RA   Sheer D., Hickson I.D.;
RT   "Isolation of cDNA clones encoding the beta isozyme of human DNA
RT   topoisomerase II and localisation of the gene to chromosome 3p24.";
RL   Nucleic Acids Res. 20:5587-5592(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8383537; DOI=10.1016/0167-4781(93)90215-y;
RA   Austin C.A., Sng J.H., Patel S., Fisher L.M.;
RT   "Novel HeLa topoisomerase II is the II beta isoform: complete coding
RT   sequence and homology with other type II topoisomerases.";
RL   Biochim. Biophys. Acta 1172:283-291(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 149-1034.
RX   PubMed=2556712; DOI=10.1073/pnas.86.23.9431;
RA   Chung T.D., Drake F.H., Tan K.B., Per S.R., Crooke S.T., Mirabelli C.K.;
RT   "Characterization and immunological identification of cDNA clones encoding
RT   two human DNA topoisomerase II isozymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9431-9435(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 910-1626.
RX   PubMed=10095062; DOI=10.1016/s0167-4781(99)00020-2;
RA   Sng J.H., Heaton V.J., Bell M., Mani P., Austin C.A., Fisher L.M.;
RT   "Molecular cloning and characterization of the human topoisomerase IIalpha
RT   and IIbeta genes: evidence for isoform evolution through gene
RT   duplication.";
RL   Biochim. Biophys. Acta 1444:395-406(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE OF 1038-1271.
RX   PubMed=2163884; DOI=10.1016/0014-5793(90)81520-x;
RA   Austin C.A., Fisher L.M.;
RT   "Isolation and characterization of a human cDNA clone encoding a novel DNA
RT   topoisomerase II homologue from HeLa cells.";
RL   FEBS Lett. 266:115-117(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 1277-1626.
RX   PubMed=9168988; DOI=10.1006/bbrc.1997.6539;
RA   Yuwen H., Hsia C.C., Nakashima Y., Evangelista A., Tabor E.;
RT   "Binding of wild-type p53 by topoisomerase II and overexpression of
RT   topoisomerase II in human hepatocellular carcinoma.";
RL   Biochem. Biophys. Res. Commun. 234:194-197(1997).
RN   [7]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8396237; DOI=10.1093/nar/21.16.3719;
RA   Davies S.L., Jenkins J.R., Hickson I.D.;
RT   "Human cells express two differentially spliced forms of topoisomerase II
RT   beta mRNA.";
RL   Nucleic Acids Res. 21:3719-3723(1993).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8299728; DOI=10.1006/excr.1994.1046;
RA   Zini N., Santi S., Ognibene A., Bavelloni A., Neri L.M., Valmori A.,
RA   Mariani E., Negri C., Astaldi-Ricotti G.C., Maraldi N.M.;
RT   "Discrete localization of different DNA topoisomerases in HeLa and K562
RT   cell nuclei and subnuclear fractions.";
RL   Exp. Cell Res. 210:336-348(1994).
RN   [9]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9155056; DOI=10.1038/bjc.1997.227;
RA   Turley H., Comley M., Houlbrook S., Nozaki N., Kikuchi A., Hickson I.D.,
RA   Gatter K., Harris A.L.;
RT   "The distribution and expression of the two isoforms of DNA topoisomerase
RT   II in normal and neoplastic human tissues.";
RL   Br. J. Cancer 75:1340-1346(1997).
RN   [10]
RP   COFACTOR, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF GLU-482;
RP   SER-485; ARG-508; LYS-510 AND ARG-515.
RX   PubMed=10684600; DOI=10.1021/bi991328b;
RA   West K.L., Meczes E.L., Thorn R., Turnbull R.M., Marshall R., Austin C.A.;
RT   "Mutagenesis of E477 or K505 in the B' domain of human topoisomerase II
RT   beta increases the requirement for magnesium ions during strand passage.";
RL   Biochemistry 39:1223-1233(2000).
RN   [11]
RP   NUCLEAR EXPORT SIGNAL.
RX   PubMed=12821127; DOI=10.1016/s0006-291x(03)01077-5;
RA   Mirski S.E., Bielawski J.C., Cole S.P.;
RT   "Identification of functional nuclear export sequences in human
RT   topoisomerase IIalpha and beta.";
RL   Biochem. Biophys. Res. Commun. 306:905-911(2003).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1336; SER-1340; SER-1400 AND
RP   SER-1413, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate cancer
RT   cells: identification of phosphoproteins in the LNCaP cell line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PLSCR1.
RX   PubMed=17567603; DOI=10.1093/nar/gkm434;
RA   Wyles J.P., Wu Z., Mirski S.E., Cole S.P.;
RT   "Nuclear interactions of topoisomerase II alpha and beta with phospholipid
RT   scramblase 1.";
RL   Nucleic Acids Res. 35:4076-4085(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1454, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1400; SER-1413 AND SER-1581,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1336; SER-1340; SER-1342;
RP   SER-1344; SER-1375; SER-1400; SER-1413; TYR-1421; SER-1424; SER-1466;
RP   SER-1550; SER-1552; SER-1581; THR-1592; SER-1596; TYR-1609 AND SER-1613,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1236; THR-1292; SER-1342;
RP   SER-1344; SER-1375; SER-1400; THR-1403; SER-1413; SER-1424; SER-1461;
RP   SER-1466; SER-1473; SER-1476; SER-1522; SER-1524; THR-1575 AND SER-1581,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1236; SER-1336; SER-1340;
RP   SER-1342; SER-1344; SER-1400; SER-1413; SER-1424; SER-1441; SER-1452;
RP   SER-1454; SER-1466; SER-1476; SER-1522; SER-1524; SER-1526 AND SER-1613,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1336; SER-1340; SER-1342;
RP   SER-1344; SER-1358; SER-1400; SER-1413; SER-1424; SER-1441; SER-1454;
RP   SER-1466; SER-1522; SER-1524; SER-1550; SER-1581 AND SER-1613, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1236; SER-1400; SER-1413;
RP   SER-1424; SER-1452; SER-1454; SER-1466; SER-1522; SER-1524; SER-1550 AND
RP   SER-1552, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1400; SER-1413; SER-1522;
RP   SER-1524; SER-1550; SER-1552; THR-1575; SER-1576 AND SER-1581, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-34; LYS-1227; LYS-1271; LYS-1440
RP   AND LYS-1456, SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-28 (ISOFORM
RP   BETA-1), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-177; LYS-373; LYS-437; LYS-605;
RP   LYS-643; LYS-1227; LYS-1440 AND LYS-1456, SUMOYLATION [LARGE SCALE
RP   ANALYSIS] AT LYS-28 (ISOFORM BETA-1), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1250, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [30]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-33; LYS-177; LYS-178; LYS-228;
RP   LYS-299; LYS-367; LYS-373; LYS-437; LYS-439; LYS-446; LYS-600; LYS-605;
RP   LYS-635; LYS-643; LYS-646; LYS-676; LYS-712; LYS-1092; LYS-1214; LYS-1217;
RP   LYS-1226; LYS-1227; LYS-1250; LYS-1262; LYS-1271; LYS-1323; LYS-1327;
RP   LYS-1398; LYS-1440; LYS-1456 AND LYS-1490, SUMOYLATION [LARGE SCALE
RP   ANALYSIS] AT LYS-28 AND LYS-29 (ISOFORM BETA-1), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [31]
RP   INVOLVEMENT IN BILU, VARIANTS BILU LEU-488; GLU-593 DEL AND SER-638,
RP   CHARACTERIZATION OF VARIANTS BILU LEU-488; GLU-593 DEL AND SER-638, AND
RP   FUNCTION.
RX   PubMed=31409799; DOI=10.1038/s41467-019-11570-6;
RA   Broderick L., Yost S., Li D., McGeough M.D., Booshehri L.M., Guaderrama M.,
RA   Brydges S.D., Kucharova K., Patel N.C., Harr M., Hakonarson H., Zackai E.,
RA   Cowell I.G., Austin C.A., Huegle B., Gebauer C., Zhang J., Xu X., Wang J.,
RA   Croker B.A., Frazer K.A., Putnam C.D., Hoffman H.M.;
RT   "Mutations in topoisomerase IIbeta result in a B cell immunodeficiency.";
RL   Nat. Commun. 10:3644-3644(2019).
RN   [32]
RP   DEUBIQUITINATION BY EPSTEIN-BARR VIRUS PROTEIN BPLF1 (MICROBIAL INFECTION),
RP   AND SUMOYLATION.
RX   PubMed=34543352; DOI=10.1371/journal.ppat.1009954;
RA   Li J., Nagy N., Liu J., Gupta S., Frisan T., Hennig T., Cameron D.P.,
RA   Baranello L., Masucci M.G.;
RT   "The Epstein-Barr virus deubiquitinating enzyme BPLF1 regulates the
RT   activity of topoisomerase II during productive infection.";
RL   PLoS Pathog. 17:e1009954-e1009954(2021).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 450-1206 IN COMPLEX WITH DNA;
RP   MAGNESIUM AND ETOPOSIDE, ACTIVE SITE, COFACTOR, AND SUBUNIT.
RX   PubMed=21778401; DOI=10.1126/science.1204117;
RA   Wu C.C., Li T.K., Farh L., Lin L.Y., Lin T.S., Yu Y.J., Yen T.J.,
RA   Chiang C.W., Chan N.L.;
RT   "Structural basis of type II topoisomerase inhibition by the anticancer
RT   drug etoposide.";
RL   Science 333:459-462(2011).
RN   [34]
RP   VARIANT TYR-63, AND INVOLVEMENT IN DEVELOPMENTAL DELAY AND AUTISM SPECTRUM
RP   DISORDER.
RX   PubMed=28343847; DOI=10.1016/j.cca.2017.03.022;
RA   Lam C.W., Yeung W.L., Law C.Y.;
RT   "Global developmental delay and intellectual disability associated with a
RT   de novo TOP2B mutation.";
RL   Clin. Chim. Acta 469:63-68(2017).
RN   [35]
RP   VARIANT BILU PRO-490, CHARACTERIZATION OF VARIANT BILU PRO-490, AND
RP   FUNCTION.
RX   PubMed=32128574; DOI=10.1182/blood.2019003299;
RA   Papapietro O., Chandra A., Eletto D., Inglott S., Plagnol V., Curtis J.,
RA   Maes M., Alisaac A., Albuquerque A.S., Basseres E., Hermine O., Picard C.,
RA   Fischer A., Durandy A., Kracker S., Burns S.O., Cuchet-Lourenco D.,
RA   Okkenhaug K., Nejentsev S.;
RT   "Topoisomerase 2beta mutation impairs early B-cell development.";
RL   Blood 135:1497-1501(2020).
RN   [36]
RP   VARIANT TYR-63, AND INVOLVEMENT IN DEVELOPMENTAL DELAY AND AUTISM SPECTRUM
RP   DISORDER.
RX   PubMed=31953910; DOI=10.1002/mgg3.1145;
RA   Hiraide T., Watanabe S., Matsubayashi T., Yanagi K., Nakashima M.,
RA   Ogata T., Saitsu H.;
RT   "A de novo TOP2B variant associated with global developmental delay and
RT   autism spectrum disorder.";
RL   Mol. Genet. Genomic Med. 8:e1145-e1145(2020).
RN   [37]
RP   VARIANT BILU GLU-593 DEL.
RX   PubMed=33459963; DOI=10.1007/s10875-020-00963-8;
RA   Erdos M., Lanyi A., Balazs G., Casanova J.L., Boisson B., Marodi L.;
RT   "Inherited TOP2B Mutation: Possible Confirmation of Mutational Hotspots in
RT   the TOPRIM Domain.";
RL   J. Clin. Immunol. 41:817-819(2021).
CC   -!- FUNCTION: Key decatenating enzyme that alters DNA topology by binding
CC       to two double-stranded DNA molecules, generating a double-stranded
CC       break in one of the strands, passing the intact strand through the
CC       broken strand, and religating the broken strand. Plays a role in B-cell
CC       differentiation. {ECO:0000269|PubMed:10684600,
CC       ECO:0000269|PubMed:31409799, ECO:0000269|PubMed:32128574}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP-dependent breakage, passage and rejoining of double-
CC         stranded DNA.; EC=5.6.2.2; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00995, ECO:0000269|PubMed:10684600};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00995, ECO:0000269|PubMed:10684600,
CC         ECO:0000269|PubMed:21778401};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00995, ECO:0000269|PubMed:10684600,
CC         ECO:0000269|PubMed:21778401};
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00995, ECO:0000269|PubMed:10684600,
CC         ECO:0000269|PubMed:21778401};
CC       Note=Binds two Mg(2+) per subunit. The magnesium ions form salt bridges
CC       with both the protein and the DNA. Can also accept other divalent metal
CC       cations, such as Mn(2+) or Ca(2+). {ECO:0000255|PROSITE-
CC       ProRule:PRU00995, ECO:0000269|PubMed:10684600,
CC       ECO:0000269|PubMed:21778401};
CC   -!- SUBUNIT: Homodimer (PubMed:21778401). Interacts with KIAA1210 (By
CC       similarity). Interacts with PLSCR1 (PubMed:19690332).
CC       {ECO:0000250|UniProtKB:Q64511, ECO:0000269|PubMed:19690332,
CC       ECO:0000269|PubMed:21778401}.
CC   -!- INTERACTION:
CC       Q02880; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-2307774, EBI-473160;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:8299728,
CC       ECO:0000269|PubMed:9155056}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:9155056}. Nucleus {ECO:0000269|PubMed:19690332}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Beta-2;
CC         IsoId=Q02880-1; Sequence=Displayed;
CC       Name=Beta-1;
CC         IsoId=Q02880-2; Sequence=VSP_006532;
CC   -!- TISSUE SPECIFICITY: Expressed in the tonsil, spleen, lymph node,
CC       thymus, skin, pancreas, testis, colon, kidney, liver, brain and lung
CC       (PubMed:9155056). Also found in breast, colon and lung carcinomas,
CC       Hodgkin's disease, large-cell non-Hodgkin's lymphoma, lymphocytic
CC       lymphomas and seminomas (PubMed:9155056). {ECO:0000269|PubMed:9155056}.
CC   -!- PTM: (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1;
CC       leading to stabilized SUMOylated TOP2A trapped in cleavage complexes,
CC       which halts the DNA damage response to TOP2A-induced double-strand DNA
CC       breaks. {ECO:0000269|PubMed:34543352}.
CC   -!- PTM: SUMOylated. {ECO:0000269|PubMed:34543352}.
CC   -!- DISEASE: Note=Defects in TOP2B may be involved in global developmental
CC       delay with autism spectrum disorder (ASD).
CC       {ECO:0000269|PubMed:28343847, ECO:0000269|PubMed:31953910}.
CC   -!- DISEASE: B-cell immunodeficiency, distal limb anomalies, and urogenital
CC       malformations (BILU) [MIM:609296]: An autosomal dominant disorder
CC       characterized by humoral immunodeficiency with undetectable B cells,
CC       distal limb anomalies, dysmorphic facial features, and urogenital
CC       malformations. {ECO:0000269|PubMed:31409799,
CC       ECO:0000269|PubMed:32128574, ECO:0000269|PubMed:33459963}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Eukaryotic topoisomerase I and II can relax both
CC       negative and positive supercoils, whereas prokaryotic enzymes relax
CC       only negative supercoils.
CC   -!- SIMILARITY: Belongs to the type II topoisomerase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X68060; CAA48197.1; -; mRNA.
DR   EMBL; X71911; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z15111; CAA78815.1; -; mRNA.
DR   EMBL; Z15115; CAA78821.1; -; mRNA.
DR   EMBL; M27504; AAA61210.1; -; mRNA.
DR   EMBL; AJ011721; CAA09753.1; -; Genomic_DNA.
DR   EMBL; AJ011722; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011723; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011724; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011725; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011726; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011727; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011728; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011729; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011730; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011731; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; AJ011732; CAA09753.1; JOINED; Genomic_DNA.
DR   EMBL; X53662; CAA37706.1; -; mRNA.
DR   EMBL; U54831; AAB01982.1; -; mRNA.
DR   CCDS; CCDS46776.1; -. [Q02880-2]
DR   CCDS; CCDS82746.1; -. [Q02880-1]
DR   PIR; S26730; A39242.
DR   RefSeq; NP_001059.2; NM_001068.3. [Q02880-2]
DR   RefSeq; NP_001317629.1; NM_001330700.2. [Q02880-1]
DR   PDB; 3QX3; X-ray; 2.16 A; A/B=450-1206.
DR   PDB; 4G0U; X-ray; 2.70 A; A/B=450-1206.
DR   PDB; 4G0V; X-ray; 2.55 A; A/B=450-1206.
DR   PDB; 4G0W; X-ray; 2.70 A; A/B=450-1206.
DR   PDB; 4J3N; X-ray; 2.30 A; A/B=450-1206.
DR   PDB; 5GWI; X-ray; 2.74 A; A/B=450-1206.
DR   PDB; 5GWJ; X-ray; 2.57 A; A/B=450-1206.
DR   PDB; 5ZAD; X-ray; 2.54 A; A/B=450-1206.
DR   PDB; 5ZEN; X-ray; 2.75 A; A=450-1206.
DR   PDB; 5ZQF; X-ray; 3.87 A; A=450-1206.
DR   PDB; 5ZRF; X-ray; 2.30 A; A/B=450-1206.
DR   PDB; 7QFN; X-ray; 2.62 A; A=50-449.
DR   PDB; 7QFO; X-ray; 1.90 A; A=50-449.
DR   PDB; 7YQ8; EM; 3.90 A; A/B=1-1626.
DR   PDB; 7ZBG; X-ray; 2.30 A; A=50-449.
DR   PDB; 8KE7; X-ray; 2.80 A; A/B=450-1206.
DR   PDBsum; 3QX3; -.
DR   PDBsum; 4G0U; -.
DR   PDBsum; 4G0V; -.
DR   PDBsum; 4G0W; -.
DR   PDBsum; 4J3N; -.
DR   PDBsum; 5GWI; -.
DR   PDBsum; 5GWJ; -.
DR   PDBsum; 5ZAD; -.
DR   PDBsum; 5ZEN; -.
DR   PDBsum; 5ZQF; -.
DR   PDBsum; 5ZRF; -.
DR   PDBsum; 7QFN; -.
DR   PDBsum; 7QFO; -.
DR   PDBsum; 7YQ8; -.
DR   PDBsum; 7ZBG; -.
DR   PDBsum; 8KE7; -.
DR   AlphaFoldDB; Q02880; -.
DR   EMDB; EMD-34022; -.
DR   SMR; Q02880; -.
DR   BioGRID; 113008; 274.
DR   CORUM; Q02880; -.
DR   FunCoup; Q02880; 3904.
DR   IntAct; Q02880; 92.
DR   MINT; Q02880; -.
DR   STRING; 9606.ENSP00000264331; -.
DR   BindingDB; Q02880; -.
DR   ChEMBL; CHEMBL3396; -.
DR   DrugBank; DB04745; 2-Hydroxyquinoline.
DR   DrugBank; DB08651; 3'-THIO-THYMIDINE-5'-PHOSPHATE.
DR   DrugBank; DB11617; Aclarubicin.
DR   DrugBank; DB06013; Aldoxorubicin.
DR   DrugBank; DB05022; Amonafide.
DR   DrugBank; DB00276; Amsacrine.
DR   DrugBank; DB04975; Banoxantrone.
DR   DrugBank; DB06362; Becatecarin.
DR   DrugBank; DB17149; Berubicin.
DR   DrugBank; DB00827; Cinoxacin.
DR   DrugBank; DB03966; Clorobiocin.
DR   DrugBank; DB00970; Dactinomycin.
DR   DrugBank; DB12804; Daniquidone.
DR   DrugBank; DB00694; Daunorubicin.
DR   DrugBank; DB06421; Declopramide.
DR   DrugBank; DB00380; Dexrazoxane.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB17026; Ellipticine.
DR   DrugBank; DB05129; Elsamitrucin.
DR   DrugBank; DB00467; Enoxacin.
DR   DrugBank; DB00445; Epirubicin.
DR   DrugBank; DB00773; Etoposide.
DR   DrugBank; DB04576; Fleroxacin.
DR   DrugBank; DB06160; Garenoxacin.
DR   DrugBank; DB12134; Gepotidacin.
DR   DrugBank; DB01177; Idarubicin.
DR   DrugBank; DB00978; Lomefloxacin.
DR   DrugBank; DB04967; Lucanthone.
DR   DrugBank; DB12622; Lupeol.
DR   DrugBank; DB01204; Mitoxantrone.
DR   DrugBank; DB00779; Nalidixic acid.
DR   DrugBank; DB01059; Norfloxacin.
DR   DrugBank; DB01051; Novobiocin.
DR   DrugBank; DB00487; Pefloxacin.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB06193; Pixantrone.
DR   DrugBank; DB01179; Podofilox.
DR   DrugBank; DB12549; Pyrazoloacridine.
DR   DrugBank; DB00817; Rosoxacin.
DR   DrugBank; DB12410; Sabarubicin.
DR   DrugBank; DB05488; Technetium Tc-99m ciprofloxacin.
DR   DrugBank; DB00444; Teniposide.
DR   DrugBank; DB04858; Tirapazamine.
DR   DrugBank; DB00385; Valrubicin.
DR   DrugBank; DB11999; Vosaroxin.
DR   DrugBank; DB19306; XK-469 free acid.
DR   DrugBank; DB06364; XR5944.
DR   DrugBank; DB06042; ZEN-012.
DR   DrugCentral; Q02880; -.
DR   GlyGen; Q02880; 4 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q02880; -.
DR   PhosphoSitePlus; Q02880; -.
DR   SwissPalm; Q02880; -.
DR   BioMuta; TOP2B; -.
DR   DMDM; 20141946; -.
DR   jPOST; Q02880; -.
DR   MassIVE; Q02880; -.
DR   PaxDb; 9606-ENSP00000396704; -.
DR   PeptideAtlas; Q02880; -.
DR   ProteomicsDB; 58133; -. [Q02880-1]
DR   ProteomicsDB; 58134; -. [Q02880-2]
DR   Pumba; Q02880; -.
DR   Antibodypedia; 3893; 292 antibodies from 36 providers.
DR   DNASU; 7155; -.
DR   Ensembl; ENST00000264331.9; ENSP00000264331.4; ENSG00000077097.17. [Q02880-1]
DR   Ensembl; ENST00000435706.6; ENSP00000396704.2; ENSG00000077097.17. [Q02880-2]
DR   GeneID; 7155; -.
DR   KEGG; hsa:7155; -.
DR   MANE-Select; ENST00000264331.9; ENSP00000264331.4; NM_001330700.2; NP_001317629.1.
DR   UCSC; uc003cdj.4; human. [Q02880-1]
DR   AGR; HGNC:11990; -.
DR   CTD; 7155; -.
DR   DisGeNET; 7155; -.
DR   GeneCards; TOP2B; -.
DR   HGNC; HGNC:11990; TOP2B.
DR   HPA; ENSG00000077097; Low tissue specificity.
DR   MalaCards; TOP2B; -.
DR   MIM; 126431; gene.
DR   MIM; 609296; phenotype.
DR   neXtProt; NX_Q02880; -.
DR   OpenTargets; ENSG00000077097; -.
DR   Orphanet; 567502; B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome.
DR   PharmGKB; PA36672; -.
DR   VEuPathDB; HostDB:ENSG00000077097; -.
DR   eggNOG; KOG0355; Eukaryota.
DR   GeneTree; ENSGT00940000157921; -.
DR   InParanoid; Q02880; -.
DR   OMA; TWTQDFK; -.
DR   OrthoDB; 276498at2759; -.
DR   PAN-GO; Q02880; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q02880; -.
DR   TreeFam; TF105282; -.
DR   BRENDA; 5.6.2.2; 2681.
DR   BRENDA; 5.99.1.3; 2681.
DR   PathwayCommons; Q02880; -.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   SignaLink; Q02880; -.
DR   SIGNOR; Q02880; -.
DR   BioGRID-ORCS; 7155; 20 hits in 1166 CRISPR screens.
DR   CD-CODE; 232F8A39; P-body.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   ChiTaRS; TOP2B; human.
DR   EvolutionaryTrace; Q02880; -.
DR   GeneWiki; TOP2B; -.
DR   GenomeRNAi; 7155; -.
DR   Pharos; Q02880; Tclin.
DR   PRO; PR:Q02880; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q02880; protein.
DR   Bgee; ENSG00000077097; Expressed in ganglionic eminence and 206 other cell types or tissues.
DR   ExpressionAtlas; Q02880; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003918; F:DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0071318; P:cellular response to ATP; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; IEA:Ensembl.
DR   GO; GO:0006265; P:DNA topological change; IDA:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:2001034; P:positive regulation of double-strand break repair via nonhomologous end joining; IEA:Ensembl.
DR   GO; GO:0045870; P:positive regulation of single stranded viral RNA replication via double stranded DNA intermediate; IMP:UniProtKB.
DR   GO; GO:0000712; P:resolution of meiotic recombination intermediates; IBA:GO_Central.
DR   GO; GO:0000819; P:sister chromatid segregation; IBA:GO_Central.
DR   CDD; cd16930; HATPase_TopII-like; 1.
DR   CDD; cd00187; TOP4c; 1.
DR   CDD; cd03481; TopoIIA_Trans_ScTopoIIA; 1.
DR   CDD; cd03365; TOPRIM_TopoIIA; 1.
DR   FunFam; 1.10.268.10:FF:000002; DNA topoisomerase 2; 1.
DR   FunFam; 3.30.1360.40:FF:000003; DNA topoisomerase 2; 1.
DR   FunFam; 3.30.1490.30:FF:000001; DNA topoisomerase 2; 1.
DR   FunFam; 3.30.230.10:FF:000008; DNA topoisomerase 2; 1.
DR   FunFam; 3.30.565.10:FF:000004; DNA topoisomerase 2; 1.
DR   FunFam; 3.40.50.670:FF:000001; DNA topoisomerase 2; 2.
DR   FunFam; 3.90.199.10:FF:000002; DNA topoisomerase 2; 1.
DR   Gene3D; 3.30.1360.40; -; 1.
DR   Gene3D; 3.30.1490.30; -; 1.
DR   Gene3D; 3.30.230.10; -; 1.
DR   Gene3D; 3.40.50.670; -; 1.
DR   Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1.
DR   Gene3D; 3.90.199.10; Topoisomerase II, domain 5; 1.
DR   Gene3D; 1.10.268.10; Topoisomerase, domain 3; 1.
DR   IDEAL; IID00462; -.
DR   InterPro; IPR050634; DNA_Topoisomerase_II.
DR   InterPro; IPR012542; DTHCT.
DR   InterPro; IPR036890; HATPase_C_sf.
DR   InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF.
DR   InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr.
DR   InterPro; IPR001241; Topo_IIA.
DR   InterPro; IPR013760; Topo_IIA-like_dom_sf.
DR   InterPro; IPR013758; Topo_IIA_A/C_ab.
DR   InterPro; IPR013757; Topo_IIA_A_a_sf.
DR   InterPro; IPR013759; Topo_IIA_B_C.
DR   InterPro; IPR013506; Topo_IIA_bsu_dom2.
DR   InterPro; IPR002205; Topo_IIA_dom_A.
DR   InterPro; IPR001154; TopoII_euk.
DR   InterPro; IPR018522; TopoIIA_CS.
DR   InterPro; IPR031660; TOPRIM_C.
DR   InterPro; IPR006171; TOPRIM_dom.
DR   InterPro; IPR034157; TOPRIM_TopoII.
DR   PANTHER; PTHR10169:SF36; DNA TOPOISOMERASE 2-BETA; 1.
DR   PANTHER; PTHR10169; DNA TOPOISOMERASE/GYRASE; 1.
DR   Pfam; PF00204; DNA_gyraseB; 1.
DR   Pfam; PF00521; DNA_topoisoIV; 1.
DR   Pfam; PF08070; DTHCT; 1.
DR   Pfam; PF02518; HATPase_c; 1.
DR   Pfam; PF01751; Toprim; 1.
DR   Pfam; PF16898; TOPRIM_C; 1.
DR   PRINTS; PR01158; TOPISMRASEII.
DR   PRINTS; PR00418; TPI2FAMILY.
DR   SMART; SM00433; TOP2c; 1.
DR   SMART; SM00434; TOP4c; 1.
DR   SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1.
DR   SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1.
DR   SUPFAM; SSF56719; Type II DNA topoisomerase; 1.
DR   PROSITE; PS52040; TOPO_IIA; 1.
DR   PROSITE; PS00177; TOPOISOMERASE_II; 1.
DR   PROSITE; PS50880; TOPRIM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Autism spectrum disorder; Disease variant; DNA-binding; Isomerase;
KW   Isopeptide bond; Magnesium; Metal-binding; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome;
KW   Topoisomerase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q64511"
FT   CHAIN           2..1626
FT                   /note="DNA topoisomerase 2-beta"
FT                   /id="PRO_0000145369"
FT   DOMAIN          476..593
FT                   /note="Toprim"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00995"
FT   DOMAIN          736..1189
FT                   /note="Topo IIA-type catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01384"
FT   REGION          363..365
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000250"
FT   REGION          1011..1020
FT                   /note="Interaction with DNA"
FT   REGION          1110..1140
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1274..1604
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1506..1512
FT                   /note="Interaction with PLSCR1"
FT                   /evidence="ECO:0000269|PubMed:17567603"
FT   MOTIF           1034..1044
FT                   /note="Nuclear export signal"
FT   COMPBIAS        1334..1344
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1358..1370
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1374..1392
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1430..1442
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1456..1466
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1539..1549
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1563..1574
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        826
FT                   /note="O-(5'-phospho-DNA)-tyrosine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01384,
FT                   ECO:0000269|PubMed:21778401"
FT   BINDING         112
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         141
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         169..171
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         182..189
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         397..399
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         482
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00995"
FT   BINDING         562
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00995"
FT   BINDING         562
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00995,
FT                   ECO:0000269|PubMed:21778401"
FT   BINDING         564
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00995,
FT                   ECO:0000269|PubMed:21778401"
FT   SITE            510
FT                   /note="Interaction with DNA"
FT   SITE            513
FT                   /note="Interaction with DNA"
FT   SITE            682
FT                   /note="Interaction with DNA"
FT   SITE            683
FT                   /note="Interaction with DNA"
FT   SITE            744
FT                   /note="Interaction with DNA"
FT   SITE            778
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00995"
FT   SITE            825
FT                   /note="Transition state stabilizer"
FT   SITE            877
FT                   /note="Important for DNA bending; intercalates between base
FT                   pairs of target DNA"
FT   SITE            952
FT                   /note="Interaction with DNA"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64511"
FT   MOD_RES         3
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64511"
FT   MOD_RES         1236
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1292
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1336
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1340
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1342
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1344
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1358
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1370
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64511"
FT   MOD_RES         1375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         1400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1403
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1413
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1421
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1454
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1466
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1473
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1476
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         1522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1524
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1526
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1550
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1552
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1575
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1576
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1581
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1592
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1596
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1609
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   CROSSLNK        33
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        34
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        177
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        178
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        228
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        299
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        367
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        373
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        437
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        439
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        446
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        600
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        605
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        635
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        643
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        646
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        712
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1092
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1214
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1217
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1226
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1227
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1250
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1262
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1271
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1323
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1327
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1398
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1440
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1456
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1490
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         24..28
FT                   /note="Missing (in isoform Beta-1)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006532"
FT   VARIANT         63
FT                   /note="H -> Y (found in patients with global developmental
FT                   delay and autism spectrum disorder; likely pathogenic;
FT                   dbSNP:rs886039770)"
FT                   /evidence="ECO:0000269|PubMed:28343847,
FT                   ECO:0000269|PubMed:31953910"
FT                   /id="VAR_079273"
FT   VARIANT         488
FT                   /note="S -> L (in BILU; loss-of-function variant in a yeast
FT                   complementation assay; dbSNP:rs2125377904)"
FT                   /evidence="ECO:0000269|PubMed:31409799"
FT                   /id="VAR_086569"
FT   VARIANT         490
FT                   /note="A -> P (in BILU; decreased protein abundance;
FT                   severely decreased DNA topoisomerase type II (double strand
FT                   cut, ATP-hydrolyzing) activity; dbSNP:rs2125377898)"
FT                   /evidence="ECO:0000269|PubMed:32128574"
FT                   /id="VAR_086570"
FT   VARIANT         593
FT                   /note="Missing (in BILU; loss-of-function variant in a
FT                   yeast complementation assay)"
FT                   /evidence="ECO:0000269|PubMed:31409799,
FT                   ECO:0000269|PubMed:33459963"
FT                   /id="VAR_086571"
FT   VARIANT         638
FT                   /note="G -> S (in BILU; loss-of-function variant in a yeast
FT                   complementation assay; dbSNP:rs2125373730)"
FT                   /evidence="ECO:0000269|PubMed:31409799"
FT                   /id="VAR_086572"
FT   MUTAGEN         482
FT                   /note="E->Q: Strongly reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:10684600"
FT   MUTAGEN         485
FT                   /note="S->A: Slightly reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:10684600"
FT   MUTAGEN         508
FT                   /note="R->E: Slightly reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:10684600"
FT   MUTAGEN         510
FT                   /note="K->E: Strongly reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:10684600"
FT   MUTAGEN         515
FT                   /note="R->Q: Slightly reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:10684600"
FT   CONFLICT        1431
FT                   /note="T -> S (in Ref. 4; CAA78821/CAA09753)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1611
FT                   /note="A -> T (in Ref. 1; CAA48197)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1621
FT                   /note="D -> H (in Ref. 4; CAA09753)"
FT                   /evidence="ECO:0000305"
FT   TURN            52..54
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           60..66
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           69..72
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          78..86
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   TURN            87..89
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          90..98
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           100..119
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          125..131
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   TURN            132..135
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          136..141
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          149..151
FT                   /evidence="ECO:0007829|PDB:7QFN"
FT   TURN            152..154
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           158..164
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           174..176
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           187..193
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          195..204
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   TURN            205..208
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          209..216
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   TURN            217..220
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          226..229
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          235..242
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           244..247
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           254..270
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          275..278
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           288..296
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          310..315
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          318..324
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          326..328
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          330..335
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          341..344
FT                   /evidence="ECO:0007829|PDB:7ZBG"
FT   HELIX           345..363
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           374..378
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          381..387
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          394..396
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           406..408
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   STRAND          409..411
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           417..424
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   TURN            425..427
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   HELIX           428..433
FT                   /evidence="ECO:0007829|PDB:7QFO"
FT   TURN            466..469
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          470..472
FT                   /evidence="ECO:0007829|PDB:4G0U"
FT   HELIX           473..475
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          477..482
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           483..491
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   TURN            494..496
FT                   /evidence="ECO:0007829|PDB:5GWJ"
FT   HELIX           497..499
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          502..507
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           514..516
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   HELIX           519..524
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           526..535
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          545..547
FT                   /evidence="ECO:0007829|PDB:4G0V"
FT   HELIX           548..551
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          555..560
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           565..581
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           583..587
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          591..594
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          598..602
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   STRAND          607..612
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   HELIX           613..617
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   HELIX           623..625
FT                   /evidence="ECO:0007829|PDB:8KE7"
FT   STRAND          630..633
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   HELIX           637..639
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   HELIX           644..650
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           652..655
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          656..660
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           664..674
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           676..678
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           679..698
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          706..710
FT                   /evidence="ECO:0007829|PDB:5ZAD"
FT   STRAND          713..715
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           716..722
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           724..735
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   TURN            739..741
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           745..757
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           765..776
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           782..793
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   TURN            814..820
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           824..826
FT                   /evidence="ECO:0007829|PDB:4J3N"
FT   HELIX           835..838
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           841..844
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          849..852
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          855..860
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           868..871
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          875..877
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          882..884
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           890..901
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          918..924
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          927..931
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          933..938
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          941..946
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           953..959
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           961..966
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          969..971
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          976..980
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          989..992
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           995..1004
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1006..1009
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          1013..1017
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          1021..1024
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   STRAND          1030..1034
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1036..1080
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1091..1100
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1107..1114
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1144..1147
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1151..1154
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1156..1177
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   HELIX           1181..1205
FT                   /evidence="ECO:0007829|PDB:3QX3"
FT   CROSSLNK        Q02880-2:28
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        Q02880-2:29
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
SQ   SEQUENCE   1626 AA;  183267 MW;  E60E9262CC68B05D CRC64;
     MAKSGGCGAG AGVGGGNGAL TWVTLFDQNN AAKKEESETA NKNDSSKKLS VERVYQKKTQ
     LEHILLRPDT YIGSVEPLTQ FMWVYDEDVG MNCREVTFVP GLYKIFDEIL VNAADNKQRD
     KNMTCIKVSI DPESNIISIW NNGKGIPVVE HKVEKVYVPA LIFGQLLTSS NYDDDEKKVT
     GGRNGYGAKL CNIFSTKFTV ETACKEYKHS FKQTWMNNMM KTSEAKIKHF DGEDYTCITF
     QPDLSKFKME KLDKDIVALM TRRAYDLAGS CRGVKVMFNG KKLPVNGFRS YVDLYVKDKL
     DETGVALKVI HELANERWDV CLTLSEKGFQ QISFVNSIAT TKGGRHVDYV VDQVVGKLIE
     VVKKKNKAGV SVKPFQVKNH IWVFINCLIE NPTFDSQTKE NMTLQPKSFG SKCQLSEKFF
     KAASNCGIVE SILNWVKFKA QTQLNKKCSS VKYSKIKGIP KLDDANDAGG KHSLECTLIL
     TEGDSAKSLA VSGLGVIGRD RYGVFPLRGK ILNVREASHK QIMENAEINN IIKIVGLQYK
     KSYDDAESLK TLRYGKIMIM TDQDQDGSHI KGLLINFIHH NWPSLLKHGF LEEFITPIVK
     ASKNKQELSF YSIPEFDEWK KHIENQKAWK IKYYKGLGTS TAKEAKEYFA DMERHRILFR
     YAGPEDDAAI TLAFSKKKID DRKEWLTNFM EDRRQRRLHG LPEQFLYGTA TKHLTYNDFI
     NKELILFSNS DNERSIPSLV DGFKPGQRKV LFTCFKRNDK REVKVAQLAG SVAEMSAYHH
     GEQALMMTIV NLAQNFVGSN NINLLQPIGQ FGTRLHGGKD AASPRYIFTM LSTLARLLFP
     AVDDNLLKFL YDDNQRVEPE WYIPIIPMVL INGAEGIGTG WACKLPNYDA REIVNNVRRM
     LDGLDPHPML PNYKNFKGTI QELGQNQYAV SGEIFVVDRN TVEITELPVR TWTQVYKEQV
     LEPMLNGTDK TPALISDYKE YHTDTTVKFV VKMTEEKLAQ AEAAGLHKVF KLQTTLTCNS
     MVLFDHMGCL KKYETVQDIL KEFFDLRLSY YGLRKEWLVG MLGAESTKLN NQARFILEKI
     QGKITIENRS KKDLIQMLVQ RGYESDPVKA WKEAQEKAAE EDETQNQHDD SSSDSGTPSG
     PDFNYILNMS LWSLTKEKVE ELIKQRDAKG REVNDLKRKS PSDLWKEDLA AFVEELDKVE
     SQEREDVLAG MSGKAIKGKV GKPKVKKLQL EETMPSPYGR RIIPEITAMK ADASKKLLKK
     KKGDLDTAAV KVEFDEEFSG APVEGAGEEA LTPSVPINKG PKPKREKKEP GTRVRKTPTS
     SGKPSAKKVK KRNPWSDDES KSESDLEETE PVVIPRDSLL RRAAAERPKY TFDFSEEEDD
     DADDDDDDNN DLEELKVKAS PITNDGEDEF VPSDGLDKDE YTFSPGKSKA TPEKSLHDKK
     SQDFGNLFSF PSYSQKSEDD SAKFDSNEED SASVFSPSFG LKQTDKVPSK TVAAKKGKPS
     SDTVPKPKRA PKQKKVVEAV NSDSDSEFGI PKKTTTPKGK GRGAKKRKAS GSENEGDYNP
     GRKTSKTTSK KPKKTSFDQD SDVDIFPSDF PTEPPSLPRT GRARKEVKYF AESDEEEDDV
     DFAMFN
//
